Gertjan Wolbink

18.9k citations

204 papers · 10.9k indexed · 2 hit papers · h-index 60

Rheumatology top 0.05%
- Rheumatoid Arthritis Research and Therapies 92
- Systemic Lupus Erythematosus Research 62
- Spondyloarthritis Studies and Treatments 19
Immunology top 0.2%
- Immunodeficiency and Autoimmune Disorders 28
- Biosimilars and Bioanalytical Methods 28
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research 28
Radiology, Nuclear Medicine and Imaging top 0.2%
- Monoclonal and Polyclonal Antibodies Research 77
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 37

Co-authors: Theo Rispens Michael T. Nurmohamed Lucien A. Aarden Ben A. C. Dijkmans Pauline A. van Schouwenburg Steven O. Stapel Willem F. Lems C. Krieckaert
Cited by: Rheumatology Immunology Hematology
Partner nations: Netherlands United States Spain

In The Last Decade

Gertjan Wolbink

198 papers receiving 10.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2007 Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
1999 C-Reactive Protein as a Cardiovascular Risk Factor

Peers

Countries citing papers authored by Gertjan Wolbink

Since Specialization

Citations

This map shows the geographic impact of Gertjan Wolbink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gertjan Wolbink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gertjan Wolbink more than expected).

Fields of papers citing papers by Gertjan Wolbink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gertjan Wolbink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gertjan Wolbink. The network helps show where Gertjan Wolbink may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gertjan Wolbink, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gertjan Wolbink Line = papers co-authored together Gertjan Wolbink links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial Maike H M Wientjes,Sadaf Atiqi,Gertjan Wolbink,Michael T. Nurmohamed,Maarten Boers,Femke Hooijberg,Theo Rispens,Annick de Vries,Ronald van Vollenhoven,Sofía Ramiro,Noortje van Herwaarden,Bart J. F. van den Bemt,Alfons A den Broeder	2025	0
2	Reference intervals of work ability and productivity loss and their use in patients with inflammatory rheumatic and musculoskeletal diseases Dafne Capelusnik,Wim Smeets,Casper Webers,Sofía Ramiro,Elena Nikiphorou,Roel Braekers,Laura Boekel,Gertjan Wolbink,Annelies Boonen	2025	1
3	Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Dahham Alsoud,Dirk Jan A. R. Moes,Zhigang Wang,Rani Soenen,Zohra Layegh,Murray L. Barclay,Tomoyuki Mizuno,Iris K. Minichmayr,Ron J. Keizer,Sebastian G. Wicha,Gertjan Wolbink,Jo Lambert,Séverine Vermeire,Annick de Vries,Konstantinos Papamichael,Núria Padullés Zamora,Erwin Dreesen	2024	8
4	Time to talk to adults with rheumatic diseases about herpes zoster vaccination M.P.B.I. Pier,Gertjan Wolbink,Laura Boekel	2024	2
5	Drug-tolerant detection of anti-drug antibodies in an antigen-binding assay using europium chelate fluorescence Jolinde van Strien,Lisanne Dijk,Sadaf Atiqi,Rogier Schouten,Karien Bloem,Gertjan Wolbink,Floris C. Loeff,Theo Rispens	2023	4
6	Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider C. Krieckaert,Borja Hernández‐Breijo,Johanna Elin Gehin,Guillaume Le Mélédo,Alejandro Balsa,Meghna Jani,Denis Mulleman,Victoria Navarro‐Compán,Gertjan Wolbink,John D. Isaacs,Astrid van Tubergen	2022	16
7	Identification of Clinically and Pathophysiologically Relevant Rheumatoid Factor Epitopes by Engineered IgG Targets Willem J.J. Falkenburg,Nienke Oskam,Jana Koers,Laurette van Boheemen,Pleuni Ooijevaar‐de Heer,Gwenny M. Verstappen,Hendrika Bootsma,Frans G. M. Kroese,Dirkjan van Schaardenburg,Gertjan Wolbink,Theo Rispens	2020	14
8	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay Lea C. Berkhout,M. l’Ami,J. Ruwaard,M. Hart,Pleuni Ooijevaar‐de Heer,Karien Bloem,Michael T. Nurmohamed,Ronald van Vollenhoven,Maarten Boers,Daniel F. Alvarez,Catherine Smith,Gertjan Wolbink,Theo Rispens	2019	41
9	FRI0186 Concomitant csdmards influence clinical response to tnf inhibitors only in overweight patients with axial spondyloarthritis Borja Hernández‐Breijo,Victoria Navarro‐Compán,Ana Martínez‐Feito,Andrea Jochems,A. Villalba,Diana Peiteado,E. Kneepkens,Pilar Nozal,Gertjan Wolbink,Theo Rispens,Dora Pascual‐Salcedo,Alejandro Balsa,Chamaida Plasencia‐Rodríguez	2018	1
10	Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial M. l’Ami,C. Krieckaert,Michael T. Nurmohamed,Ronald van Vollenhoven,Theo Rispens,Maarten Boers,Gertjan Wolbink	2017	53
11	Anti-Hinge Antibodies Recognize IgG Subclass– and Protease-Restricted Neoepitopes Willem J.J. Falkenburg,Dirkjan van Schaardenburg,Pleuni Ooijevaar‐de Heer,Michel Tsang-A-Sjoe,Irene E. M. Bultink,Alexandre E. Voskuyl,Arthur E. H. Bentlage,Gestur Vidarsson,Gertjan Wolbink,Theo Rispens	2016	23
12	Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange Karin A. van Schie,Pleuni Ooijevaar‐de Heer,Lisanne Dijk,Simone Kruithof,Gertjan Wolbink,Theo Rispens	2016	46
13	Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies Pauline A. van Schouwenburg,Simone Kruithof,Christian Votsmeier,Karin van Schie,M. Hart,Rob N. de Jong,Esther E.L. van Buren,S. Marieke van Ham,Lucien A. Aarden,Gertjan Wolbink,Diana Wouters,Theo Rispens	2014	54
14	Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects C. Krieckaert,Sandhya Nair,Michael T. Nurmohamed,C.J.J. van Dongen,Willem F. Lems,F.P.J.G. Lafeber,J. W. J. Bijlsma,Hendrik Koffijberg,Gertjan Wolbink,Paco M J Welsing	2013	77
15	Comparison of long‐term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity C. Krieckaert,Anna Jamnitski,Michael T. Nurmohamed,Piet J. Kostense,Maarten Boers,Gertjan Wolbink	2012	54
16	The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia – A Prospective Cohort Study Maarten Limper,L.A. van de Stadt,Wouter H Bos,Martijn D. de Kruif,C. Arnold Spek,Gertjan Wolbink,Dirkjan van Schaardenburg,Eric C. M. Van Gorp	2012	12
17	Tumour necrosis factor α blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study M.J. Peters,Paul Welsh,Iain B. McInnes,Gertjan Wolbink,Ben A. C. Dijkmans,Naveed Sattar,Michael T. Nurmohamed	2009	46
18	The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels Wouter H Bos,Jennie Ursum,Niek de Vries,G. M. Bartelds,Gertjan Wolbink,Michael T. Nurmohamed,Irene E. van der Horst‐Bruinsma,R J van de Stadt,J. Bart A. Crusius,Paul P. Tak,Ben A. C. Dijkmans,Dirkjan van Schaardenburg	2008	22
19	Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study Justin Pijpe,Gustaaf W. van Imhoff,Fred K. L. Spijkervet,Jan L.N. Roodenburg,Gertjan Wolbink,Khaled Mansour,Arjan Vissink,C. G. M. Kallenberg,Hendrika Bootsma	2005	356
20	The release of interleukin-8 during intravenous bolus treatment with interleukin-2 Johanna W. Baars,Gertjan Wolbink,M. Hart,C. Erik Hack,A J Eerenberg-Belmer,Herbert M. Pinedo,John Wagstaff	1994	11

About Gertjan Wolbink

Gertjan Wolbink is a scholar working on Rheumatology, Immunology and Genetics, having authored 204 papers that have together received 10.9k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (92 papers), Monoclonal and Polyclonal Antibodies Research (77 papers), Systemic Lupus Erythematosus Research (62 papers), Chronic Lymphocytic Leukemia Research (37 papers), Autoimmune and Inflammatory Disorders Research (28 papers), Immunodeficiency and Autoimmune Disorders (28 papers), Biosimilars and Bioanalytical Methods (28 papers) and Spondyloarthritis Studies and Treatments (19 papers). The work is most often cited by research in Rheumatology (4.5k citations), Immunology (4.8k citations) and Hematology (1.5k citations). Gertjan Wolbink has collaborated with scholars based in Netherlands, United States and Spain. Frequent co-authors include Theo Rispens, Michael T. Nurmohamed, Lucien A. Aarden, Ben A. C. Dijkmans, Pauline A. van Schouwenburg, Steven O. Stapel, Willem F. Lems, C. Krieckaert, G. M. Bartelds and Hans W.M. Niessen.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact